Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 3465 - 3472 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC8040 | MPC 6827 hydrochloride |
|
Potent inhibitor of microtubule formation (IC50 = 1.5 - 3.4 nM); inhibits polymerization of tubulin in vitro and disrupts microtubule formation in several cancer cell lines. Inhibits tumor growth in vitro and in vivo; exhibits pro-apoptotic characteristics. Brain penetrant.
|
|
| BCC8041 | Huwentoxin XVI |
|
Potent and selective N-type Ca2+ channel blocker (IC50 ~ 60 nM); selectively and reversibly blocks N-type Ca2+ channels. Does not block T-type Ca2+ channels, K+ channels or Na+ channels. Exhibits analgesic effects in vivo.
|
|
| BCC8042 | UC 112 |
|
IAP inhibitor (IC<sub>50</sub> values from 0.7 - 3.4 <span class='symbol'>μ</span>M); inhibits cell growth in multiple cancer cell lines and in a melanoma xenograft model <em>in vivo</em>. Also suppresses X-linked inhibitor of apoptosis protein (XIAP) and survivin levels. Inhibits the growth of P-glycoproteins and activates caspase-3/7 and caspase-9.
|
|
| BCC8043 | 6-Bnz-cAMP sodium salt |
|
Cell permeable cAMP analog; selectively activates cAMP-dependent PKA but not Epac signaling pathways. Acts synergistically with 8-CPT-2Me-cAMP to inhibit vascular smooth muscle cell proliferation.
|
|
| BCC8044 | AH 7614 |
|
Selective free fatty acid receptor 4 (FFA4/GPR120) antagonist (pIC<sub>50</sub> values are 7.1 and <4.6 for human FFA4 and FFA1 receptors respectively). Inhibits linoleic acid and GSK 137647A</a>-induced intracellular calcium accumulation in U2OS osteosarcoma cells expressing the FFA4 receptor.
|
|
| BCC8046 | BMS 309403 |
|
Potent and selective fatty acid binding protein 4, adipocyte (FABP4) inhibitor (Ki values are <2, 250 and 350 nM for FABP4, FABP3 and FABP5 respectively). Decreases fatty acid uptake in adipocytes in vitro and reduces atherosclerotic lesion area in a mouse model of atherosclerosis. Reduces blood glucose levels and increases insulin sensitivity in a mouse model of obesity. Orally active.
|
|
| BCC8047 | Toyocamycin |
|
Adenosine analog; antifungal antibiotic. Inhibits RNA self-cleavage in HEK79 cells and PI 3-kinase activity in A431 epidermoid carcinoma cell membrane fractions. Also inhibits thapsigargin-induced XBP1-luciferase activation and induces apoptosis in multiple myeloma cell lines.
|
|
| BCC8051 | WH-4-023 |
|
Potent and selective Lck and Src inhibitor (IC<sub>50</sub> values are 2 and 6 nM respectively). Exhibits >300-fold selectivity against p38<span class='symbol'>α</span> and KDR. Also potently inhibits SIK (IC<sub>50</sub> values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases. Supports self-renewal of naive hESCs in combination with PD 0325901, CHIR 99021 and SB 590885.
|
|